ArticleAnnals of hematology2026
Comparison of clinical outcomes between early and delayed allogeneic hematopoietic stem cell transplantation for severe aplastic anemia: a single-center retrospective study.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is the only curative therapy for severe aplastic anemia (SAA), yet the prognostic impact of the diagnostic-to-transplant interval on first allo-HSCT remains contentious. To determine whether a waiting time > 1 year from diagnosis to first allo-HSCT compromises engraftment, virus reactivation, GVHD, OS and GRFS in SAA. A single-center retrospective cohort study of 255 consecutive SAA patients receiving their first allo-HSCT between 2018 and 2025. After 1:2 propensity-score matching (caliiper 0.2), patients were stratified into Early (≤ 1 year, n = 170) and Delayed (> 1 year, n = 85) groups. Baseline characteristics were well balanced. The Early group exhibited a significantly lower CMV reactivation rate (24.1% vs. 40.0%, P = 0.008). No significant differences were observed in grade II-IV aGVHD, cGVHD, 5-year OS or GRFS. Subgroup analyses demonstrated superior survival among patients aged ≤ 40 years, those with MSD donors and received FABT-based regimen. Early allo-HSCT improves transplant outcomes in SAA by reducing CMV reactivation, especially in very severe cases. Eligible patients should be referred promptly and transplanted without delay.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.